[Objective] To evaluate the efficacy and surgical safety of transforaminal endoscopic debridement of the lesion of brucellosis spondylitis in the lower lumbar spine (L4/5, L5 S1) . [Methods] A retrospective study was conducted on 16 patients who underwent transforami- nal endoscopic debridement of the lesion of brucellosis spondylitis in the lower lumbar spine from January 2014 to August 2022. Clinical and laboratory data of patients were summarized. [Results] All the patients had operation performed successfully with no complications such as nerve and dural injury, got significantly relief of lumbago and nerve symptoms of lower extremity and well incision healing postoperatively. The body temperature decreased from (38.6±1.2)℃ before surgery to (37.6±0.7)℃ 2 days after surgery and (36.5±0.4)℃ at the last follow-up (P＜0.05); the VAS score for pain significantly decreased [(6.3±1.3), (3.7±1.2), (1.1±0.9), P＜0.05]; the ODI score significantly decreased [(67.4±9.5)%, (36.1±6.1)%, (12.3±4.1)%, P＜0.05] . However, the JOA score significantly increased from (8.9±3.0) to (14.5±3.9) and (25.6± 1.6) (P＜0.05) . In terms of laboratory test, the ESR significantly decreased from (51.9±33.3) mm/h preoperatively to (34.3±16.0) mm/h 2 days postoperatively, and (10.6±4.2) mm/h at the latest follow-up (P＜0.05) . CRP decreased significantly from (46.6±34.0) mg/L to (30.2±18.9) mg/L and postoperative (3.0±1.4) mg/L accordingly (P＜0.05) . [Conclusion] This transforaminal endoscopic debridement of the lesion of brucellosis spondylitis in the lower lumbar spine is less invasive, safer and has satisfactory clinical results.